In the landscape of oncology, few challenges have been as persistent as the management of non-metastatic castration-sensitive prostate cancer (nmCSPC) following initial definitive therapy. When patients experience a rising prostate-specific antigen (PSA) level—a condition known as biochemical recurrence (BCR)—the transition toward metastatic disease has long been a looming threat. However, the international Phase III EMBARK trial (NCT02319837) has fundamentally altered the clinical calculus for these patients, providing a landmark dataset that has reshaped global treatment guidelines.
In a recent expert-led discussion, Dr. Neal Shore, Medical Director of the Carolina Urologic Research Center, and Dr. Henry Woo, a leading academic urological surgeon from Sydney, Australia, dissected the findings of this pivotal trial. Their conversation highlights how the use of enzalutamide, both in combination with androgen deprivation therapy (ADT) and as a monotherapy, is providing patients with a vital extension of life and quality of care.
Main Facts: The EMBARK Trial Overview
The EMBARK study was designed as an international, randomized, Phase III clinical trial to evaluate the efficacy and safety of enzalutamide—an androgen receptor pathway inhibitor (ARPI)—in patients with high-risk nmCSPC who were experiencing biochemical recurrence.
Historically, the standard of care for these patients was leuprolide, a form of ADT. EMBARK sought to determine if intensifying this treatment could delay the onset of metastasis. The study enrolled 1,068 patients across 244 sites in 17 countries, with enrollment spanning from 2015 to 2018. The trial utilized a unique three-arm design:
- Combination Therapy: Enzalutamide plus leuprolide.
- Monotherapy: Enzalutamide alone (an open-label arm).
- Control: Leuprolide plus placebo (the standard-of-care benchmark).
A defining feature of the trial was its approach to treatment duration. Investigators implemented a "treatment suspension" strategy at week 37, provided the patient’s PSA levels had fallen below 0.2 ng/mL. Therapy was only reinitiated if PSA levels reached specific thresholds (5.0 ng/mL for those without prior radical prostatectomy, or 2.0 ng/mL for those who had undergone the procedure). This "off-time" from therapy was a novel clinical construct designed to balance the prevention of metastasis with the mitigation of the toxicities typically associated with long-term hormonal suppression.
Chronology: From Concept to Global Approval
The journey of the EMBARK trial reflects the rigorous nature of modern oncological research.
- 2015–2018: The active enrollment phase saw over 1,000 patients join the trial globally.
- 2019: Following the publication of trials regarding non-metastatic castration-resistant prostate cancer (nmCRPC), such as SPARTAN, PROSPER, and ARAMIS, the EMBARK investigators adjusted their protocol to ensure that patients who progressed to a certain level of risk were offered the best possible care, maintaining the highest ethical standards.
- 2023: The results were presented as a plenary session at the American Urological Association (AUA) annual meeting, sparking immediate global interest. Simultaneously, findings were published in the New England Journal of Medicine (NEJM).
- Post-2023: Following the dissemination of the 5-year follow-up data, the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) granted approvals for the use of enzalutamide in this high-risk population.
Supporting Data: Efficacy and Quality of Life
The primary endpoint of the EMBARK study was metastasis-free survival (MFS), a metric widely accepted as a surrogate for overall survival in prostate cancer.
Efficacy Findings
After a median follow-up of 60.7 months, the data were definitive. The combination of enzalutamide and leuprolide significantly outperformed leuprolide alone. The 5-year MFS was 87% in the combination group, compared to 71% in the leuprolide-only group. Notably, the combination therapy reduced the risk of metastasis or death by 58% (Hazard Ratio [HR] 0.42).
Perhaps most surprising and impactful was the success of the enzalutamide monotherapy arm. As a secondary endpoint, it also demonstrated a statistically significant improvement in MFS compared to the control, with a 37% lower risk of metastasis or death (HR 0.63). This provided clinicians with a potent alternative to traditional ADT, which is often associated with significant physical and psychological side effects.
Safety and Patient-Reported Outcomes (PROs)
A primary concern with intensifying prostate cancer treatment is the impact on quality of life. The EMBARK investigators closely monitored adverse events (AEs) and patient-reported outcomes.
While 97% of patients across all groups reported an AE of some grade, the nature of these events varied. Fatigue and hot flashes remained common across all groups. However, patients on enzalutamide monotherapy reported fewer hot flashes compared to those on leuprolide-containing regimens. Conversely, monotherapy was associated with a higher incidence of gynecomastia and breast tenderness. Crucially, the study found that health-related quality of life was preserved across all treatment arms. The Functional Assessment of Cancer Therapy-Prostate (FACT-P) scores remained stable, confirming that the benefits of disease control did not come at the expense of daily well-being.
Official Responses and Clinical Implications
The implications of the EMBARK trial have rippled through major oncological organizations, with the trial’s results now integrated into international treatment guidelines.
Shared Decision-Making
Dr. Shore emphasizes that the availability of enzalutamide monotherapy in the high-risk BCR setting marks a paradigm shift. "We now have a tool that allows for a nuanced, shared decision-making process," he notes. Clinicians can discuss with patients the pros and cons of combination therapy versus monotherapy, taking into account the patient’s lifestyle, tolerance for specific side effects, and desire to avoid the metabolic and hormonal sequelae associated with traditional ADT.
The Role of Modern Imaging
One of the most vital areas for future clinical practice is the integration of PSMA PET imaging. While the EMBARK trial relied on conventional imaging, the rise of PSMA PET—which can detect micrometastatic disease earlier—presents a new challenge. Clinicians must now decide how to interpret EMBARK’s findings for patients whose recurrence might be identified via PET scans before it is visible on standard imaging. This remains an area of active research and ongoing clinical debate.
Limitations and Future Directions
Despite the success of the trial, the investigators remain cautious. The overall survival data are currently immature, though trending positively. Furthermore, the underrepresentation of non-White patient populations in the study is a recognized limitation, highlighting the need for broader diversity in future clinical trials. Additionally, the long-term consequences of prolonged ARPI exposure are still being characterized, necessitating continued vigilance in post-market surveillance and long-term patient follow-up.
Conclusion: A More Invigorating Path Forward
The EMBARK trial has provided a robust, evidence-based foundation for treating patients with high-risk biochemical recurrence. By demonstrating that enzalutamide, both in combination and as monotherapy, can delay the spread of cancer while maintaining patient quality of life, the study has moved the goalposts for urologists and oncologists globally.
As Dr. Woo noted, while the study has answered critical questions, it has also whetted the appetite for more. The intellectual rigor required to manage these patients—balancing the intensity of therapy against the preservation of their lifestyle—is what keeps the field of urologic oncology moving forward. For the patient facing the anxiety of a rising PSA, EMBARK offers something that was previously in short supply: time, clarity, and the promise of a more personalized approach to treatment.
As the medical community continues to analyze the long-term data and integrate these findings into daily practice, the legacy of the EMBARK trial will undoubtedly be the empowerment of both the physician and the patient to take control of the disease before it takes control of them.
About the Author
